A5057922763- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Esophageal and GI Pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Gastrointestinal disorders and treatments
- Palliative Care and End-of-Life Issues
- Colorectal Cancer Surgical Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Gastrointestinal Tumor Research and Treatment
- Liver Disease Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Enhanced Recovery After Surgery
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Hemodynamic Monitoring and Therapy
Thomas Jefferson University
2016-2025
Sidney Kimmel Cancer Center
2018-2025
Thomas Jefferson University Hospital
2015-2024
Johns Hopkins Hospital
2024
Jefferson College of Health Sciences
2022
Jefferson College
2012-2022
Johns Hopkins University
2022
University Hospitals of Cleveland
2021-2022
American College of Surgeons
2022
Philadelphia University
2013-2020
Objective: To use the concept of benchmarking to establish robust and standardized outcome references after pancreatico-duodenectomy (PD). Background: Best achievable results PD are unknown. Consequently, comparisons among different cohorts, centers or with novel surgical techniques remain speculative. Methods: This multicenter study analyzes consecutive patients (2012–2015) undergoing in 23 international expert pancreas surgery. Outcomes without significant comorbidities major vascular...
Background and Objective: Robotic distal pancreatectomy (DP) is an emerging attractive approach, but its role compared with laparoscopic or open surgery remains unclear. Benchmark values are novel objective tools for such comparisons. The aim of this study was to identify benchmark cutoffs many outcome parameters DP without splenectomy beyond the learning curve. Methods: This analyzed outcomes from international expert centers patients undergoing robotic malignant benign lesions. After...
The KRAS proto-oncogene is a major driver of pancreatic tumorigenesis and nearly ubiquitously mutated in ductal adenocarcinoma (PDAC). point mutations are detected over 90% PDAC cases, these have been shown to be associated with worse therapy response overall survival. Pathogenic mostly limited codons 12, 13 61, G12D, G12V, G12R, Q61H, G13D accounting for approximately 95% the mutant cases. Emerging data importance specific subtypes, as well variant allele frequency on clinical prognosis....
Background: Early invasive carcinoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The natural history these early lesions is unknown. Methods: Pancreatic surgical databases from 4 high-volume centers were queried for IPMNs, components measuring 20 mm or less. All cases reviewed by GI gastrointestinal pathologists, and pathologic features analyzed to identify predictors recurrence survival. Results: A total 70 small IPMN-associated...
Objective: The aim of this study was to establish clinically relevant outcome benchmark values using criteria for pancreatoduodenectomy (PD) with portomesenteric venous resection (PVR) from a low-risk cohort managed in high-volume centers. Summary Background Data: PD PVR is regarded as the standard care patients cancer involvement axis. There are, however, no indicators population which hampers comparisons undergoing and without resection. Methods: This multicenter analyzed any type 23...
This study was designed to determine whether the volume and type of fluid administered for pancreaticoduodenectomy impacts postoperative outcomes.Three percent hypertonic saline (HYS) has been suggested as a means reducing required sustain tissue perfusion in perioperative period.Between May 2011 November 2013, patients undergoing were enrolled an institutional review board-approved, single-center, prospective, parallel, randomized controlled trial (NCT 01428050), comparing lactated Ringers...
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas (HAPa); IND# 12311] immunotherapy combined with standard care (SOC) chemotherapy chemoradiation to SOC therapy alone in patients borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: date, has not been shown benefit unresectable PDAC. HAPa is a cancer vaccine consisting allogeneic cells engineered express murine α(1,3)GT gene. Methods: A multicenter,...
Pancreatic cancer (PC) is one of the most aggressive and challenging types to effectively treat, ranking as fourth-leading cause death in United States. We investigated if exposures angiotensin II receptor blockers (ARBs) or I converting enzyme (ACE) inhibitors after PC diagnosis are associated with survival.PC patients were identified by ICD-9 procedure codes among 3.7 million adults living Emilia-Romagna Region from their administrative health care database containing patient data on...
Abstract Purpose: Heritable genetic variations can affect the inflammatory tumor microenvironment, which ultimately cancer susceptibility and clinical outcomes. Recent evidence indicates that IDO2, a positive modifier in disease models, is frequently upregulated pancreatic ductal adenocarcinoma (PDAC). A unique feature of IDO2 humans high prevalence two inactivating single-nucleotide polymorphisms (SNP), affords opportunity to carry out loss-of-function studies directly humans. In this...
Objective: The aim of this study was to evaluate whether neoadjuvant therapy (NAT) critically influenced microscopically complete resection (R0) rates and long-term outcomes for patients with pancreatic ductal adenocarcinoma who underwent pancreatoduodenectomy (PD) portomesenteric vein (PVR) from a diverse, world-wide group high-volume centers. Summary Background Data: Limited size studies suggest that NAT improves R0 overall survival compared upfront surgery in R/BR-PDAC patients. Methods:...
The aim of this study was to evaluate the different phases learning curve for robotic distal pancreatectomy (RDP) in international expert centers.